Get the Stockscreener App
1.60
0.63%
0.01
After Hours:
1.60
Pmv Pharmaceuticals Inc stock is traded at $1.60, with a volume of 121.60K.
It is up +0.63% in the last 24 hours and down -3.61% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
See More
Previous Close:
$1.59
Open:
$1.59
24h Volume:
121.60K
Relative Volume:
0.63
Market Cap:
$84.35M
Revenue:
-
Net Income/Loss:
$-68.96M
P/E Ratio:
-0.9816
EPS:
-1.63
Net Cash Flow:
$-56.62M
1W Performance:
+1.91%
1M Performance:
-3.61%
6M Performance:
-21.57%
1Y Performance:
-31.33%
1-Day Range:
$1.59
$1.64
1-Week Range:
$1.56
$1.68
52-Week Range:
$1.40
$3.47
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6664
Address
ONE RESEARCH WAY, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.60 | 84.35M | 0 | -68.96M | -56.62M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer - MSN
Sionna Therapeutics Appoints Laurie Stelzer to its Board of Directors - citybiz
ArrowMark Colorado Holdings LLC Expands Stake in PMV Pharmaceuti - GuruFocus.com
BML Capital Management LLC Grows Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Icahn Enterprises Releases Third Quarter 2024 Financial Results - Defense World
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Receives $5.80 Average Target Price from Brokerages - MarketBeat
PMV Pharmaceuticals (NASDAQ:PMVP) Upgraded at Oppenheimer - MarketBeat
Oppenheimer raises PMVP rating to Outperform, sets stock target on Q3 results - Investing.com UK
PMV Pharmaceuticals Inc (PMVP) Quarterly 10-Q Report - Quartz
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Manila Times
Duos Edge AI Acquires Additional Edge Data Centers - The Manila Times
Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors - OncLive
Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer - OncLive
US Penny Stocks To Consider In October 2024 - Simply Wall St
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial - GlobeNewswire
New Global Hematology Journal Strives to Feature Innovative and Adaptable Research - OncLive
SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Menin Inhibitors for AML: A Roundtable on the Latest Advances - OncLive
SG Americas Securities LLC Grows Stake in Stellantis (NYSE:STLA) - Defense World
ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML - OncLive
Envestnet Asset Management Inc. Sells 2,501 Shares of Juniper Networks, Inc. (NYSE:JNPR) - Defense World
Point72 Asia Singapore Pte. Ltd. Takes $101,000 Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
Pawan Singh sharing his grief with Mata Rani, asking questions from his mind, Pawan Singh sharing his grief with Mata Rani, asking questions from his mind - AnyTV News
Small Cap Stocks: Plexus, Parkmead, Proton Motor - The Armchair Trader
Stock market news: PC Jeweller shares hit 5% upper circuit- Check Details - MSN
Vanguard Personalized Indexing Management LLC Increases Position in PDD Holdings Inc. (NASDAQ:PDD) - Defense World
2 ASX shares I can’t ignore: PME and SOL - Rask Media
40% women with PCOD may get diabetes: Experts - The Times of India
Parvin Dabas, Pro Panja League Co-Founder, In ICU After Road Accident - Pratidin Time
Agency News | ⚡Pro Panja League Co-Founder and Actor Parvin Dabas Admitted to ICU Following Car Accident - LatestLY
Should PME shares be on your watchlist? - Rask Media
Power Mech Shares Gain on Securing Orders Worth Rs 865 Crore - EquityPandit
Power Mech rises on Rs 865-cr order win from Vedanta's subsidiary - Business Standard
Bowers & Wilkins Launches Px7 S2e “Ruby Red” and Px8 “Dark Forest” - HYPEBEAST
Bowers & Wilkins adds two new colors to PX7 S2e & PX8 headphones - Gstyle magazine
PMV Pharmaceuticals executive sells over $10k in company stock By Investing.com - Investing.com Canada
PMV Pharmaceuticals CFO sells over $4,300 in company stock By Investing.com - Investing.com Canada
PMV Pharmaceuticals executive sells over $10k in company stock - Investing.com India
Insider Selling: PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells 7,218 Shares of Stock - MarketBeat
PMV Pharmaceuticals CFO sells over $4,300 in company stock - Investing.com India
Wharton San Diego Presents: The Future of Biotechnology in San Diego - Procopio
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCL - OncLive
Closing Figures: PMV Pharmaceuticals Inc (PMVP)’s Negative Finish at 1.58, Down -1.25 - The Dwinnex
Assenagon Asset Management S.A. Has $401,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Envestnet Portfolio Solutions Inc. Buys 5,351 Shares of MBIA Inc. (NYSE:MBI) - Defense World
Dr El-Jawahri on the Effects of Sexual Health Interventions in HSCT Recipients - OncLive
Assenagon Asset Management S.A. Boosts Stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
PMV Pharmaceuticals, Inc. to Post Q3 2024 Earnings of ($0.35) Per Share, HC Wainwright Forecasts (NASDAQ:PMVP) - MarketBeat
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):